论文部分内容阅读
目的:探讨乳腺癌转移抑制因子(BRMSl)、细胞缝隙连接蛋白43(Cx43)在甲状腺癌中的表达变化及与患者临床病理特征、预后复发的关系。方法:收集术后确诊的甲状腺癌组织标本(甲状腺癌组)102例、因外科其他原因进行甲状腺活检或手术采集的正常甲状腺组织标本40例(正常组)、手术后确诊为甲状腺良性疾病67例(良性组,包括甲状腺腺瘤、结节性甲状腺肿),采用免疫组织化学法检测三组中的BRMSl、Cx43蛋白表达情况并进行分析。结果:甲状腺癌组织中BRMSl、Cx43蛋白的阳性表达率分别为49.02%、46.07%,均明显低于良性组和正常组,且差异均具有统计学意义(P<0.05);甲状腺癌组织中BRMSl、Cx43蛋白的阳性表达率与患者的淋巴结转移、包膜侵犯、肿瘤直径、TNM分期有关(P<0.05);甲状腺癌组织中BRMSl、Cx43蛋白阳性表达患者的5年复发率和病死率为4.00%、5.13%,均明显低于阴性表达患者的19.23%、20.00%(P<0.05)。结论:BRMSl、Cx43在甲状腺组织中下调表达与甲状腺癌的发生、发展及预后具有一定的关系。
Objective: To investigate the expression of breast cancer metastasis suppressor factor (BRMSl) and connexin43 (Cx43) in thyroid cancer and its relationship with clinicopathological features and recurrence. Methods: Tissue specimens of thyroid cancer (thyroid cancer group) diagnosed in 102 cases were collected. Forty thyroid tissue specimens (normal group) collected by thyroid biopsy or surgery for other reasons were collected. 67 cases of thyroid benign diseases were diagnosed after operation (Benign group, including thyroid adenoma and nodular goiter). The expression of BRMS1 and Cx43 protein in the three groups were detected by immunohistochemistry and analyzed. Results: The positive rates of BRMS1 and Cx43 in thyroid cancer tissues were 49.02% and 46.07%, respectively, which were significantly lower than those in benign and normal thyroid tissues (P <0.05) (P <0.05). The 5-year recurrence rate and case fatality rate of patients with positive expression of BRMS1 and Cx43 in thyroid cancer tissues were 4.00 % And 5.13%, respectively, were significantly lower than the negative expression of 19.23%, 20.00% (P <0.05). Conclusion: Down-regulated expression of BRMS1 and Cx43 in thyroid tissue has a certain relationship with the occurrence, development and prognosis of thyroid cancer.